GT200300244A - Isomeros posicionales del ifn peg alfa 2a - Google Patents

Isomeros posicionales del ifn peg alfa 2a

Info

Publication number
GT200300244A
GT200300244A GT200300244A GT200300244A GT200300244A GT 200300244 A GT200300244 A GT 200300244A GT 200300244 A GT200300244 A GT 200300244A GT 200300244 A GT200300244 A GT 200300244A GT 200300244 A GT200300244 A GT 200300244A
Authority
GT
Guatemala
Prior art keywords
alfa
positional isomers
ifn
peg
ifn peg
Prior art date
Application number
GT200300244A
Other languages
English (en)
Inventor
Doris Brugger
Stefan Foser
Alfred Schacher
Karl Weyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300244A publication Critical patent/GT200300244A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION CONCIERNE CON ISOMEROS POSICIONALES DEL INTERFERON ALFA 2A MONOPEGILADO, CON UN METODO PARA SU AISLAMIENTO Y PARA SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES, ESPECIALMENTE LAS CAUSADAS POR VIRUS. POR LO ANTERIOR, LA INVENCION ES DE UTILIDAD EN CASOS DE HEPATITIS C.
GT200300244A 2002-11-15 2003-11-13 Isomeros posicionales del ifn peg alfa 2a GT200300244A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02025585 2002-11-15

Publications (1)

Publication Number Publication Date
GT200300244A true GT200300244A (es) 2004-06-03

Family

ID=32319537

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300244A GT200300244A (es) 2002-11-15 2003-11-13 Isomeros posicionales del ifn peg alfa 2a

Country Status (23)

Country Link
US (1) US20040223950A1 (es)
EP (1) EP1562634B1 (es)
JP (1) JP4279258B2 (es)
KR (1) KR20050065677A (es)
CN (1) CN1323722C (es)
AR (1) AR042039A1 (es)
AT (1) ATE337017T1 (es)
AU (1) AU2003293668A1 (es)
BR (1) BR0316227A (es)
CA (1) CA2503594C (es)
DE (1) DE60307881T2 (es)
ES (1) ES2270152T3 (es)
GT (1) GT200300244A (es)
MX (1) MXPA05005178A (es)
NO (1) NO20052310L (es)
PA (1) PA8587801A1 (es)
PE (1) PE20040834A1 (es)
PL (1) PL376883A1 (es)
RU (1) RU2005118752A (es)
TW (1) TW200413404A (es)
UY (1) UY28080A1 (es)
WO (1) WO2004045648A1 (es)
ZA (1) ZA200503756B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
KR20050086498A (ko) * 2002-11-18 2005-08-30 맥시겐, 인크. 인터페론-알파 폴리펩티드 및 접합체
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
AU2006262151A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2009030066A1 (fr) * 2007-09-04 2009-03-12 Biosteed Gene Expression Tech. Co., Ltd. Interféron alpha 2b modifié par du polyethylèneglycol et procédé de préparation et applications associés
KR101483814B1 (ko) * 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
PL2272875T3 (pl) * 2008-04-03 2014-06-30 Biosteed Gene Expression Tech Co Ltd Hormon wzrostu modyfikowany dwuniciowym glikolem polietylenowym, sposoby otrzymywania i stosowania
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
ES2875426T3 (es) 2008-04-29 2021-11-10 Ascendis Pharma Endocrinology Div A/S Compuestos de hormona de crecimiento humana recombinante pegilada
DE102009009344B4 (de) * 2009-02-05 2018-01-04 Helmholtz-Zentrum Dresden - Rossendorf E.V. Verfahren und Anordnung zur Reinigung des Reaktionsgemisches bei der Herstellung von Radiopharmaka
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
JP2006508918A (ja) * 2002-09-05 2006-03-16 ザ ジェネラル ホスピタル コーポレーション 修飾されたアシアロインターフェロンおよびその使用

Also Published As

Publication number Publication date
JP2006515571A (ja) 2006-06-01
PE20040834A1 (es) 2004-11-17
PL376883A1 (pl) 2006-01-09
US20040223950A1 (en) 2004-11-11
KR20050065677A (ko) 2005-06-29
BR0316227A (pt) 2005-10-04
JP4279258B2 (ja) 2009-06-17
CA2503594A1 (en) 2004-06-03
EP1562634B1 (en) 2006-08-23
DE60307881D1 (de) 2006-10-05
ZA200503756B (en) 2008-02-27
ES2270152T3 (es) 2007-04-01
EP1562634A1 (en) 2005-08-17
CA2503594C (en) 2011-05-10
WO2004045648A1 (en) 2004-06-03
MXPA05005178A (es) 2005-07-22
NO20052310D0 (no) 2005-05-11
ATE337017T1 (de) 2006-09-15
NO20052310L (no) 2005-08-09
AU2003293668A1 (en) 2004-06-15
PA8587801A1 (es) 2004-09-16
AR042039A1 (es) 2005-06-08
UY28080A1 (es) 2004-05-31
DE60307881T2 (de) 2007-03-08
CN1711109A (zh) 2005-12-21
TW200413404A (en) 2004-08-01
CN1323722C (zh) 2007-07-04
RU2005118752A (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
GT200300244A (es) Isomeros posicionales del ifn peg alfa 2a
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
UY28084A1 (es) Derivados antivirales de nucleosidos
UY28581A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
AR052165A1 (es) Tratamiento de hepatitis c en la poblacion asiatica
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
EA201591702A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
ECSP055801A (es) Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
DK1658302T3 (da) Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
CR8273A (es) Administracion de ligandos de tlr7 y profarmacos de los mismos para el tratamiento de la infeccion por el virus de hepetitis c
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
BR122020006906B8 (pt) compostos e composições farmacêuticas antivirais
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
UY28313A1 (es) Nonadepsipeptidos acilados
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
UY27733A1 (es) Derivados de ciclopenteno.
UY38435A (es) Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
NO20045579L (no) Behandling av hepatitt C i den asiatiske populasjonen med subkutan interferon beta
EA200501344A1 (ru) Комбинированное применение рибавирина и бета-интерферона при демиелинизирующих заболеваниях
UY28954A1 (es) Tratamiento de la miocardiopatía y la disfunción endotelial
ES2140329B1 (es) Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
EA200501625A1 (ru) Интерферон-бета при тяжелом остром респираторном синдроме (sars)
BRPI0406985A (pt) Terapia de combinação de hcv